BioCentury
ARTICLE | Clinical News

AnaptysBio plans study of first-in-class IL-36R antagonist

April 17, 2015 1:06 AM UTC

Antibody platform company AnaptysBio Inc. (San Diego, Calif.) began IND-enabling studies of first-in-class IL-36R antagonist ANB019 to treat generalized pustular psoriasis (GPP), a rare but life-threatening inherited form of psoriasis for which there are no approved biologic treatments. ANB019 replaces a genetic defect in the natural IL36R antagonist in GPP patients. AnaptysBio plans to begin a first-in-human study of ANB019 in healthy volunteers next year. ...